Table 1.
Demographic and medication characteristics.
| GG | TAU | |||||
|---|---|---|---|---|---|---|
| N | Mean | Std. | N | Mean | Std. | |
| deviation | deviation | |||||
| Age (years) | 12 | 37.3 | 10.9 | 55 | 44.6 | 15.7 |
| Age of onset (years) | 12 | 27.3 | 10.0 | 54 | 36.4 | 16.1 |
| Number of episodes | 12 | 7.4 | 8.1 | 51 | 3.4 | 4.0 |
| Duration current episode (weeks) | 12 | 25.1 | 16.9 | 51 | 23.5 | 39.4 |
| BMI kg/m2 | 12 | 29.9 | 7.7 | 51 | 27.8 | 5.5 |
| Number/(%) | Number/(%) | |||||
| Gender m/f | 7/5 | 23/32 | ||||
| SSRI/SNRI | 12 | 9 (75%) | 55 | 44 (80.0%) | ||
| Tricyclic | 12 | 1 (8.3%) | 55 | 4 (7.2%) | ||
| Mirtazapin | 12 | 0 | 55 | 12 (21.8%) | ||
| MAO inhibitors | 12 | 1 (8.3%) | 55 | 3 (5.4%) | ||
| Lithium | 12 | 1 (8.3%) | 55 | 8 (14.5%) | ||
| Atypical neuroleptics | 12 | 4 (25.0%) | 55 | 24 (43.6%) | ||
| Low dose typical neuroleptics | 12 | 3 (25.0%) | 55 | 16 (29.0%) | ||
| None | 12 | 1 (8.3%) | 55 | 0 | ||